Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Psoriasis: Update Bulletin #3 [April 2018]

Product Code:
596200953
Publication Date:
April 2018
Format:
PDF
Price:
£910

This edition presents key opinion leader (KOL) views on recent developments in the treatment of psoriasis. Topics covered include; KOL views on AbbVie’s presentation of positive results from two pivotal Phase III trials with interleukin-23 (IL-23) inhibitor risankizumab, including head-to-head data with competitor Stelara (ustekinumab; Janssen Biotech); KOL views on the Food and Drug Administration’s (FDA) approval of second-in-class interleukin-23 (IL-23) inhibitor Ilumya (tildrakizumab; Sun Pharmaceuticals) in March 2018; and views on two orally administered novel therapies for the treatment of moderate-to-severe psoriasis, including Bristol Myers Squibb’s tyrosine kinase 2 (Tyk2) inhibitor BMS-986165 and MetrioPharm’s macrophage modulator MP1032.

Business Questions:

• In February 2018, AbbVie presented positive results from the UltiMMa-1 and UltiMMa-2 Phase III clinical trials, illustrating the superiority of interleukin-23 (IL-23) inhibitor risankizumab compared with marketed biological therapy Stelara (ustekinumab; Janssen Biotech), but how do key opinion leaders perceive the data from these pivotal trials?
• If approved, how can risankizumab differentiate itself from an increasingly crowded market populated with efficacious biological therapies? 
• How and where in the treatment paradigm for moderate-to-severe psoriasis will risankizumab be used? 
• How do key opinion leaders perceive Sun Pharmaceuticals’ second-in-class IL-23 inhibitor Ilumya (tildrakizumab)?
• Ilumya met the primary endpoints in the reSURFACE Phase III development program, but are the results sufficient to establish this product as a viable competitor to marketed biological therapies for the treatment of moderate-to-severe psoriasis?
• Bristol Myers Squibb’s BMS-986165 represents a novel approach in the treatment of moderate-to-severe psoriasis, targeting tyrosine kinase 2 (Tyk2), but how viable do opinion leaders consider this mechanism of action, and what concerns if any do they have about inhibiting this pathway?
• If approved, where in the treatment paradigm will BMS-986165 sit, and what products will it compete with?
• How do opinion leaders view MetrioPharm’s novel macrophage targeting therapy MP1032 in the treatment of moderate-to-severe psoriasis?
• As MP1032 moves into Phase IIb development, how optimistic are opinion leaders with regard to the potential of this product?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved